Compare VOXR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | XOMA |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.5M | 308.6M |
| IPO Year | 2022 | N/A |
| Metric | VOXR | XOMA |
|---|---|---|
| Price | $6.14 | $26.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | ★ 760.7K | 235.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.95 | $77.29 |
| Revenue Next Year | $89.38 | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $18.40 |
| 52 Week High | $5.94 | $39.92 |
| Indicator | VOXR | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 53.59 |
| Support Level | $4.86 | $23.71 |
| Resistance Level | N/A | $27.73 |
| Average True Range (ATR) | 0.30 | 1.28 |
| MACD | 0.07 | 0.38 |
| Stochastic Oscillator | 97.65 | 79.08 |
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.